Skip to main content
SpringerLink
Log in

Infectious Complications: Prevention and Management

  • Chapter
  • First Online:
Kidney and Pancreas Transplantation

Part of the book series: Current Clinical Urology ((CCU))

  • 1710 Accesses

Abstract

Infections are a major source of complications in the posttransplant period. This chapter reviews practical approaches to pretransplant screening of donor and recipient, and management of posttransplant bacterial, viral, fungal, and parasitic infections with an emphasis on prevention and early detection. We review recent developments, including increasing antimicrobial resistance which pose challenges for antibiotic management. In addition, suggestions for immunizations and avoiding environmental exposures are presented.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Fishman JA, Rubin RH. Infection in organ-transplant recipients. NEJM 1998;338(24):1741–1751.

    Article  PubMed  CAS  Google Scholar 

  2. Fishman JA. Infection in solid-organ transplant recipients. NEJM 2007;357(25):2601–2614.

    Article  PubMed  CAS  Google Scholar 

  3. AST Infectious Diseases Community of Practice. The American Society of Transplantation Infectious Disease Guidelines, Second Edition. Am J Transplant 2009;9 Suppl 4:S1-S281.

    Google Scholar 

  4. Richeldi L, et al. Performance of tests for latent tuberculosis in different groups of immunocompromised patients. Chest 2009;136(1):198–204.

    Article  PubMed  Google Scholar 

  5. Fischer SA, et al. Transmission of lymphocytic choriomeningitis virus by organ transplantation. NEJM 2006;354(21):2235–2249.

    Article  PubMed  CAS  Google Scholar 

  6. Rubin RH. Infection in the organ transplant recipient. In Rubin RH, Young LS (eds.). Clinical Approach to Infection in the Compromised Host, 4th edn. New York: Plenum, 2002.

    Chapter  Google Scholar 

  7. Dharnidharka VR, Agodoa LY, Abbott KC. Risk factors for hospitalization for bacterial or viral infection in renal transplant recipients – an analysis of USRDS data. Am J Transplant 2007;7(3):653–661.

    Article  PubMed  CAS  Google Scholar 

  8. Dharnidharka VR, Stablein DM, Harmon WE. Post-transplant infections now exceed acute rejection as cause for hospitalization: a report of the NAPRTCS. Am J Transplant 2004;4(3):384–389.

    Article  PubMed  Google Scholar 

  9. Puliyanda DP, Stablein DM, Dharnidharka VR. Younger age and antibody induction increase the risk for infection in pediatric renal transplantation: a NAPRTCS report. Am J Transplant 2007;7(3):662–666.

    Article  PubMed  CAS  Google Scholar 

  10. Snyder JJ, et al. Rates of first infection following kidney transplant in the United States. Kidney Int 2009;75(3):317–326.

    Article  PubMed  Google Scholar 

  11. Linares L, et al. Infection-related mortality in a large cohort of renal transplant recipients. Transplant Proc 2007;39(7):2225–2227.

    Article  PubMed  CAS  Google Scholar 

  12. Thai NL, et al. Pancreas transplantation under alemtuzumab (Campath-1H) and tacrolimus: correlation between low T-cell responses and infection. Transplantation 2006;82(12):1649–1652.

    Article  PubMed  CAS  Google Scholar 

  13. Mawhorter S, Yamani MH. Hypogammaglobulinemia and infection risk in solid organ transplant recipients. Curr Opin Organ Transplant 2008;13(6):581–585.

    PubMed  Google Scholar 

  14. Broeders EN, et al. Evolution of immunoglobulin and mannose binding protein levels after renal transplantation: association with infectious complications. Transpl Int 2008;21(1):57–64.

    PubMed  CAS  Google Scholar 

  15. Manuel O, et al. Association between mannose-binding lectin deficiency and cytomegalovirus infection after kidney transplantation. Transplantation 2007;83(3):359–362.

    Article  PubMed  CAS  Google Scholar 

  16. Rodrigo E, et al. Cytokine polymorphisms and risk of infection after kidney transplantation. Transplant Proc 2007;39(7):2219–2221.

    Article  PubMed  CAS  Google Scholar 

  17. Issa NC, Fishman JA. Infectious complications of antilymphocyte therapies in solid organ transplantation. Clin Infect Dis 2009;48(6):772–786.

    Article  PubMed  CAS  Google Scholar 

  18. Haririan A, et al. Sirolimus exposure during the early post-transplant period reduces the risk of CMV infection relative to tacrolimus in renal allograft recipients. Clin Transplant 2007;21(4):466–471.

    Article  PubMed  Google Scholar 

  19. Demopoulos L, et al. Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials. Transplant Proc 2008;40(5):1407–1410.

    Article  PubMed  CAS  Google Scholar 

  20. Hanvesakul R, et al. Increased incidence of infections following the late introduction of mycophenolate mofetil in renal transplant recipients. Nephrol Dial Transplant 2008;23(12):4049–4053.

    Article  PubMed  CAS  Google Scholar 

  21. Woeste G, et al. Value of donor swabs for intra-abdominal infection in simultaneous pancreas- kidney transplantation. Transplantation 2003;76(7):1073–1078.

    Article  PubMed  Google Scholar 

  22. Berger N, et al. Bloodstream infection following 217 consecutive systemic-enteric drained pancreas transplants. BMC Infect Dis 2006;6:127.

    Article  PubMed  Google Scholar 

  23. Kim RD, et al. Impact of mode of dialysis on intra-abdominal infection after simultaneous pancreas-kidney transplantation. Transplantation 2005;80(3):339–343.

    Article  PubMed  Google Scholar 

  24. Ramos A, et al. Incisional surgical site infection in kidney transplantation. Urology, 2008;72(1):119–123.

    Article  PubMed  Google Scholar 

  25. Menezes FG, et al. Risk factors for surgical site infection in kidney transplant recipients. Infect Control Hosp Epidemiol 2008;29(8):771–773.

    Article  PubMed  Google Scholar 

  26. Berger N, et al. Infectious complications following 72 consecutive enteric-drained pancreas transplants. Transpl Int 2006;19(7):549–557.

    Article  PubMed  CAS  Google Scholar 

  27. Papalois BE, et al. Long-term peritoneal dialysis before transplantation and intra-abdominal infection after simultaneous pancreas-kidney transplantations. Arch Surg 1996;131(7):761–766.

    Article  PubMed  CAS  Google Scholar 

  28. Everett JE, et al. Characterization and impact of wound infection after pancreas transplantation. Arch Surg 1994;129(12):1310–1316; discussion 1316–1317.

    Article  PubMed  CAS  Google Scholar 

  29. Schaffer M, et al. Morbidity and mortality of kidney and pancreas transplantation. Analysis of 810 transplantations at one center. Dtsch Med Wochenschr 2007;132(44):2318–2322.

    Article  PubMed  CAS  Google Scholar 

  30. Gruessner RW, et al. The surgical risk of pancreas transplantation in the cyclosporine era: an overview. J Am Coll Surg 1997;185(2):128–144.

    Article  PubMed  CAS  Google Scholar 

  31. Steurer W, et al. Incidence of intraabdominal infection in a consecutive series of 40 enteric-drained pancreas transplants with FK506 and MMF immunosuppression. Transpl Int 2000;13(Suppl 1):S195–198.

    PubMed  Google Scholar 

  32. Benedetti E, et al. Pancreas graft loss caused by intra-abdominal infection. A risk factor for a subsequent pancreas retransplantation. Arch Surg 1996;131(10):1054–1060.

    Article  PubMed  CAS  Google Scholar 

  33. Knight RJ, et al. Risk factors for intra-abdominal infection after pancreas transplantation. Am J Surg 2000;179(2):99–102.

    Article  PubMed  CAS  Google Scholar 

  34. Perdiz LB, et al. Incidence and risk factors for surgical site infection after simultaneous pancreas-kidney transplantation. J Hosp Infect 2009;72(4):326–331.

    Article  PubMed  CAS  Google Scholar 

  35. Hanish SI, et al. Obesity predicts increased overall complications following pancreas transplantation. Transplant Proc 2005;37(8):3564–3566.

    Article  PubMed  CAS  Google Scholar 

  36. Jimenez C, et al. Influence of dialysis modality on complications and patient and graft survival after pancreas-kidney transplantation. Transplant Proc 2008;40(9):2999–3000.

    Article  PubMed  CAS  Google Scholar 

  37. Pirsch JD, et al. Posttransplant infection in enteric versus bladder-drained simultaneous pancreas-kidney transplant recipients. Transplantation 1998;66(12):1746–1750.

    Article  PubMed  CAS  Google Scholar 

  38. Linares L, et al. Epidemiology and outcomes of multiple antibiotic-resistant bacterial infection in renal transplantation. Transplant Proc 2007;39(7):2222–2224.

    Article  PubMed  CAS  Google Scholar 

  39. Linares L, et al. Risk factors for infection with extended-spectrum and AmpC beta-lactamase-producing gram-negative rods in renal transplantation. Am J Transplant 2008;8(5):1000–1005.

    Article  PubMed  CAS  Google Scholar 

  40. Al-Hasan MN, et al. Incidence rate and outcome of Gram-negative bloodstream infection in solid organ transplant recipients. Am J Transplant 2009;9(4):835–843.

    Article  PubMed  CAS  Google Scholar 

  41. Saemann M, Horl WH. Urinary tract infection in renal transplant recipients. Eur J Clin Invest 2008;38(Suppl 2):58–65.

    Article  PubMed  Google Scholar 

  42. de Souza RM, Olsburgh J. Urinary tract infection in the renal transplant patient. Nat Clin Pract Nephrol 2008;4(5):252–264.

    Article  PubMed  Google Scholar 

  43. Rizvi SJ, et al. Significance of pretransplant urinary tract infection in short-term renal allograft function and survival. Transplant Proc 2008;40(4):1117–1118.

    Article  PubMed  CAS  Google Scholar 

  44. Puliatti C, et al. Cyst infection in renal allograft recipients with adult polycystic kidney disease: the diagnostic value of labeled leukocyte scanning: case reports. Transplant Proc 2007;39(6):1841–1842.

    Article  PubMed  CAS  Google Scholar 

  45. Rice JC, et al. Renal allograft injury is associated with urinary tract infection caused by Escherichia coli bearing adherence factors. Am J Transplant 2006;6(10):2375–2383.

    Article  PubMed  CAS  Google Scholar 

  46. Sollinger HW, et al. Two hundred consecutive simultaneous pancreas-kidney transplants with bladder drainage. Surgery 1993;114(4):736–743; discussion 743–744.

    PubMed  CAS  Google Scholar 

  47. Dharnidharka VR, Agodoa LY, Abbott KC. Effects of urinary tract infection on outcomes after renal transplantation in children. Clin J Am Soc Nephrol 2007;2(1):100–106.

    Article  PubMed  Google Scholar 

  48. Kalil AC, et al. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005;143(12):870–880.

    PubMed  Google Scholar 

  49. Alberu J, et al. Long-term renal graft function and survival in patients with high-risk for cytomegalovirus infection receiving preemptive therapy. Rev Invest Clin 2008;60(5):365–374.

    PubMed  Google Scholar 

  50. Rayes N, et al. Long-term outcome of cytomegalovirus infection in simultaneous pancreas-kidney transplant recipients without ganciclovir prophylaxis. Transpl Int 2007;20(11):974–981.

    Article  PubMed  Google Scholar 

  51. Malaise J, et al. Cytomegalovirus infection in simultaneous pancreas-kidney transplantation. Transplant Proc 2005;37(6):2848–2850.

    Article  PubMed  CAS  Google Scholar 

  52. Becker BN, et al. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation. Am J Kidney Dis 2002;39(5):1088–1095.

    Article  PubMed  Google Scholar 

  53. Singh N. Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: a call to heed the mounting evidence. Clin Infect Dis 2005. 40(5):704–708.

    Article  PubMed  Google Scholar 

  54. Singh N, et al. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease. Transplantation 2005;79(1):85–90.

    Article  PubMed  CAS  Google Scholar 

  55. Khoury JA, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006;6(9):2134–2143.

    Article  PubMed  CAS  Google Scholar 

  56. Lo A, et al. Patterns of cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone with ganciclovir prophylaxis. Transpl Infect Dis 2001;3(1):8–15.

    Article  PubMed  CAS  Google Scholar 

  57. Paya C, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004;4(4):611–620.

    Article  PubMed  CAS  Google Scholar 

  58. Boutolleau D, et al. Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection. Antiviral Res 2009;81(2):174–1749.

    Article  PubMed  CAS  Google Scholar 

  59. Eid AJ, et al. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin Transplant 2008;22(2):162–170.

    Article  PubMed  Google Scholar 

  60. Marfori JE, et al. Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. J Clin Virol 2007;38(2):120–125.

    Article  PubMed  CAS  Google Scholar 

  61. Asberg A, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007;7(9):2106–2113.

    Article  PubMed  CAS  Google Scholar 

  62. Asberg A, et al. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant 2009;9(5):1205–1213.

    Article  PubMed  CAS  Google Scholar 

  63. Green M, et al. Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease. Transplantation 1998;66(12):1641–1644.

    Article  PubMed  CAS  Google Scholar 

  64. McDiarmid SV, et al. Prevention and preemptive therapy of posttransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998;66(12):1604–1611.

    Article  PubMed  CAS  Google Scholar 

  65. Lumbreras C, et al. Infectious complications following pancreatic transplantation: incidence, microbiological and clinical characteristics, and outcome. Clin Infect Dis 1995;20(3):514–520.

    Article  PubMed  CAS  Google Scholar 

  66. Hibberd PL, et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial. Ann Intern Med 1995;123(1):18–26.

    PubMed  CAS  Google Scholar 

  67. Keay S, et al. Posttransplantation lymphoproliferative disorder associated with OKT3 and decreased antiviral prophylaxis in pancreas transplant recipients. Clin Infect Dis 1998;26(3):596–600.

    Article  PubMed  CAS  Google Scholar 

  68. Hibberd PL, et al. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation 1992;53(1):68–72.

    Article  PubMed  CAS  Google Scholar 

  69. Funch DP, et al. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 2005;5(12):2894–2900.

    Article  PubMed  CAS  Google Scholar 

  70. Singh N, Carrigan DR. Human herpesvirus-6 in transplantation: an emerging pathogen. Ann Intern Med 1996;124(12):1065–1071.

    PubMed  CAS  Google Scholar 

  71. Razonable RR, et al. Herpesvirus infections in solid organ transplant patients at high risk of primary cytomegalovirus disease. J Infect Dis 2005;192(8):1331–1339.

    Article  PubMed  Google Scholar 

  72. Josephson MA, et al. Treatment of renal allograft polyoma BK virus infection with leflunomide. Transplantation 2006;81(5):704–710.

    Article  PubMed  CAS  Google Scholar 

  73. Hariharan S. BK virus nephritis after renal transplantation. Kidney Int 2006;69(4):655–662.

    Article  PubMed  CAS  Google Scholar 

  74. Ramos E, et al. The decade of polyomavirus BK-associated nephropathy: state of affairs. Transplantation 2009;87(5):621–630.

    Article  PubMed  Google Scholar 

  75. Vats A, et al. Quantitative viral load monitoring and cidofovir therapy for the management of BK virus-associated nephropathy in children and adults. Transplantation 2003;75(1):105–112.

    Article  PubMed  CAS  Google Scholar 

  76. Benavides CA, et al. BK virus-associated nephropathy in sirolimus-treated renal transplant patients: incidence, course, and clinical outcomes. Transplantation 2007;84(1):83–88.

    Article  PubMed  CAS  Google Scholar 

  77. Duclos AJ, et al. Prevalence and clinical course of BK virus nephropathy in pancreas after kidney transplant patients. Transplant Proc 2006;38(10):3666–3672.

    Article  PubMed  CAS  Google Scholar 

  78. Smith JM, et al. BK virus nephropathy in pediatric renal transplant recipients: an analysis of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry. Clin J Am Soc Nephrol 2007;2(5):1037–1042.

    Article  PubMed  Google Scholar 

  79. Ramos E, et al. BK virus nephropathy diagnosis and treatment: experience at the University of Maryland Renal Transplant Program. Clin Transpl 2002:143–153.

    Google Scholar 

  80. Hirsch HH, et al. Polyomavirus-associated nephropathy in renal transplantation: critical issues of screening and management. Adv Exp Med Biol 2006;577:160–173.

    Article  PubMed  CAS  Google Scholar 

  81. Hirsch HH, et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation 2005;79(10):1277–1286.

    Article  PubMed  Google Scholar 

  82. Trofe J, Hirsch HH, Ramos E. Polyomavirus-associated nephropathy: update of clinical management in kidney transplant patients. Transpl Infect Dis 2006;8(2):76–85.

    Article  PubMed  CAS  Google Scholar 

  83. Comoli P, Hirsch HH, Ginevri F. Cellular immune responses to BK virus. Curr Opin Organ Transplant 2008;13(6):569–574.

    Article  PubMed  Google Scholar 

  84. Sener A, et al. Intravenous immunoglobulin as a treatment for BK virus associated nephropathy: one-year follow-up of renal allograft recipients. Transplantation 2006;81(1):117–120.

    Article  PubMed  CAS  Google Scholar 

  85. Randhawa PS. Anti-BK virus activity of ciprofloxacin and related antibiotics. Clin Infect Dis 2005;41(9):1366–1367; author reply 1367.

    Article  PubMed  Google Scholar 

  86. Josephson MA, et al. Polyomavirus-associated nephropathy: update on antiviral strategies. Transpl Infect Dis 2006;8(2):95–101.

    Article  PubMed  CAS  Google Scholar 

  87. Faguer S, et al. Leflunomide treatment for polyomavirus BK-associated nephropathy after kidney transplantation. Transpl Int 2007;20(11):962–969.

    Article  PubMed  CAS  Google Scholar 

  88. Hirsch HH, Ramos E. Retransplantation after polyomavirus-associated nephropathy: just do it? Am J Transplant 2006;6(1):7–9.

    Article  PubMed  CAS  Google Scholar 

  89. Ramos E, et al. Retransplantation in patients with graft loss caused by polyoma virus nephropathy. Transplantation 2004;77(1):131–133.

    Article  PubMed  Google Scholar 

  90. Kamar N, et al. Entecavir therapy for adefovir-resistant hepatitis B virus infection in kidney and liver allograft recipients. Transplantation 2008;86(4):611–614.

    Article  PubMed  CAS  Google Scholar 

  91. Younossi ZM, et al. Chronic viral hepatitis in renal transplant recipients with allografts functioning for more than 20 years. Transplantation 1999;67(2):272–275.

    Article  PubMed  CAS  Google Scholar 

  92. Pereira BJ, et al. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney Int 1998;53(5):1374–1381.

    Article  PubMed  CAS  Google Scholar 

  93. Natov SN, Pereira BJ. Transmission of viral hepatitis by kidney transplantation: donor evaluation and transplant policies (Part 1: hepatitis B virus). Transpl Infect Dis 2002;4(3):117–123.

    Article  PubMed  CAS  Google Scholar 

  94. Wei HK, et al. HBsAg(+) donor as a kidney transplantation deceased donor. Transplant Proc 2008;40(7):2097–2099.

    Article  PubMed  Google Scholar 

  95. Wachs ME, et al. The risk of transmission of hepatitis B from HBsAg(–), HBcAb(+), HBIgM(–) organ donors. Transplantation 1995;59(2):230–234.

    PubMed  CAS  Google Scholar 

  96. Madayag RM, et al. Use of renal allografts from donors positive for hepatitis B core antibody confers minimal risk for subsequent development of clinical hepatitis B virus disease. Transplantation 1997;64(12):1781–1786.

    Article  PubMed  CAS  Google Scholar 

  97. Chung RT, Feng S, Delmonico FL. Approach to the management of allograft recipients following the detection of hepatitis B virus in the prospective organ donor. Am J Transplant 2001;1(2):185–191.

    Article  PubMed  CAS  Google Scholar 

  98. Rosengard BR, et al. Report of the Crystal City meeting to maximize the use of organs recovered from the cadaver donor. Am J Transplant 2002;2(8):701–711.

    Article  PubMed  Google Scholar 

  99. Abbott KC, et al. The impact of transplantation with deceased donor hepatitis c-positive kidneys on survival in wait-listed long-term dialysis patients. Am J Transplant 2004;4(12):2032–2037.

    Article  PubMed  Google Scholar 

  100. Abbott KC, et al. Hepatitis C and renal transplantation in the era of modern immunosuppression. J Am Soc Nephrol 2003;14(11):2908–2918.

    Article  PubMed  Google Scholar 

  101. Abbott KC, et al. Impact of diabetes and hepatitis after kidney transplantation on patients who are affected by hepatitis C virus. J Am Soc Nephrol 2004;15(12):3166–3174.

    Article  PubMed  Google Scholar 

  102. Natov SN, et al. Hepatitis C virus genotype does not affect patient survival among renal transplant candidates. The New England Organ Bank Hepatitis C Study Group. Kidney Int 1999;56(2):700–706.

    Article  PubMed  CAS  Google Scholar 

  103. Berenguer M. Treatment of chronic hepatitis C in hemodialysis patients. Hepatology 2008;48(5):1690–1699.

    Article  PubMed  CAS  Google Scholar 

  104. Terrault NA, Adey DB. The kidney transplant recipient with hepatitis C infection: pre- and posttransplantation treatment. Clin J Am Soc Nephrol 2007;2(3):563–575.

    Article  PubMed  CAS  Google Scholar 

  105. Martin P, Fabrizi F. Hepatitis C virus and kidney disease. J Hepatol 2008;49(4):613–624.

    Article  PubMed  CAS  Google Scholar 

  106. Gallego E, et al. Effect of isolation measures on the incidence and prevalence of hepatitis C virus infection in hemodialysis. Nephron Clin Pract 2006;104(1):c1–6.

    Article  PubMed  Google Scholar 

  107. Natov SN, Pereira BJ. Hepatitis C virus in chronic dialysis patients. Minerva Urol Nefrol 2005;57(3):175–197.

    PubMed  CAS  Google Scholar 

  108. Jadoul M, Cornu C, van Ypersele de Strihou C. Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian Multicenter Study. The Universitaires Cliniques St-Luc (UCL) Collaborative Group. Kidney Int 1998;53(4):1022–1025.

    Article  PubMed  CAS  Google Scholar 

  109. Gerolami R, et al. Hepatitis E virus as an emerging cause of chronic liver disease in organ transplant recipients. J Hepatol 2009;50(3):622–624.

    Article  PubMed  Google Scholar 

  110. Aggarwal R. Hepatitis E: does it cause chronic hepatitis? Hepatology 2008;48(4):1328–1330.

    Article  PubMed  Google Scholar 

  111. Kamar N, et al. Hepatitis E virus-related cirrhosis in kidney- and kidney-pancreas-transplant recipients. Am J Transplant 2008;8(8):1744–1748.

    Article  PubMed  CAS  Google Scholar 

  112. Roland ME, et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant 2008;8(2):355–365.

    Article  PubMed  CAS  Google Scholar 

  113. Krinzman S, et al. Respiratory syncytial virus-associated infections in adult recipients of solid organ transplants. J Heart Lung Transplant 1998;17(2):202–210.

    PubMed  CAS  Google Scholar 

  114. Emovon OE, et al. Refractory adenovirus infection after simultaneous kidney-pancreas transplantation: successful treatment with intravenous ribavirin and pooled human intravenous immunoglobulin. Nephrol Dial Transplant 2003;18(11):2436–2438.

    Article  PubMed  CAS  Google Scholar 

  115. Mathur SC, et al. Adenovirus infection of the renal allograft with sparing of pancreas graft function in the recipient of a combined kidney-pancreas transplant. Transplantation 1998;65(1):138–141.

    Article  PubMed  CAS  Google Scholar 

  116. Paternoster DM, et al. Human papilloma virus infection and cervical intraepithelial neoplasia in transplanted patients. Transplant Proc 2008;40(6):1877–1880.

    Article  PubMed  CAS  Google Scholar 

  117. Beckhoff A, et al. Relapsing severe anaemia due to primary parvovirus B19 infection after renal transplantation: a case report and review of the literature. Nephrol Dial Transplant 2007;22(12):3660–3663.

    Article  PubMed  Google Scholar 

  118. Ki CS, et al. Incidence and clinical significance of human parvovirus B19 infection in kidney transplant recipients. Clin Transplant 2005;19(6):751–755.

    Article  PubMed  Google Scholar 

  119. Westhoff TH, et al. Chronic norovirus infection in renal transplant recipients. Nephrol Dial Transplant 2009;24(3):1051–1053.

    Article  PubMed  Google Scholar 

  120. Kumar D, et al. Community-acquired West Nile virus infection in solid-organ transplant recipients. Transplantation 2004;77(3):399–402.

    Article  PubMed  Google Scholar 

  121. Arend SM, et al. Rejection treatment and cytomegalovirus infection as risk factors for Pneumocystis carinii pneumonia in renal transplant recipients. Clin Infect Dis 1996;22(6):920–925.

    Article  PubMed  CAS  Google Scholar 

  122. Safdar N, et al. Predictors and outcomes of candiduria in renal transplant recipients. Clin Infect Dis 2005;40(10):1413–1421.

    Article  PubMed  CAS  Google Scholar 

  123. Battaglia M, et al. True mycotic arteritis by Candida albicans in 2 kidney transplant recipients from the same donor. J Urol 2000;163(4):1236–1237.

    Article  PubMed  CAS  Google Scholar 

  124. Mai H, et al. Candida albicans arteritis transmitted by conservative liquid after renal transplantation: a report of four cases and review of the literature. Transplantation 2006;82(9):1163–1167.

    Article  PubMed  Google Scholar 

  125. Matignon M, et al. Outcome of renal transplantation in eight patients with Candida sp. contamination of preservation fluid. Am J Transplant 2008;8(3):697–700.

    Article  PubMed  CAS  Google Scholar 

  126. Singh N, et al. An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin Infect Dis 2005;40(12):1756–1761.

    Article  PubMed  CAS  Google Scholar 

  127. Singh N, et al. Allograft loss in renal transplant recipients with Cryptococcus neoformans associated immune reconstitution syndrome. Transplantation 2005;80(8):1131–1133.

    Article  PubMed  Google Scholar 

  128. Kontoyiannis DP, et al. Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis. Antimicrob Agents Chemother 2008;52(2):735–738.

    Article  PubMed  CAS  Google Scholar 

  129. Cuellar-Rodriguez J, et al. Histoplasmosis in solid organ transplant recipients: 10 years of experience at a large transplant center in an endemic area. Clin Infect Dis 2009;49(5):710–716.

    Article  PubMed  CAS  Google Scholar 

  130. Blair JE. Coccidioidomycosis in patients who have undergone transplantation. Ann NY Acad Sci 2007;1111:365–376.

    Article  PubMed  Google Scholar 

  131. Blair JE. Approach to the solid organ transplant patient with latent infection and disease caused by Coccidioides species. Curr Opin Infect Dis 2008;21(4):415–420.

    Article  PubMed  Google Scholar 

  132. Husain S, et al. Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis 2003;37(2):221–229.

    Article  PubMed  Google Scholar 

  133. Walsh TJ, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46(3):327–360.

    Article  PubMed  CAS  Google Scholar 

  134. Singh N, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006;81(3):320–326.

    Article  PubMed  CAS  Google Scholar 

  135. Riddle DJ, Dubberke ER. Clostridium difficile infection in solid organ transplant recipients. Curr Opin Organ Transplant 2008;13(6):592–600.

    Article  PubMed  Google Scholar 

  136. Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis 1998;27(5):1266–1277.

    Article  PubMed  CAS  Google Scholar 

  137. Lattes R, et al. Tuberculosis in renal transplant recipients. Transpl Infect Dis 1999;1(2):98–104.

    Article  PubMed  CAS  Google Scholar 

  138. Vachharajani TJ, et al. Tuberculosis in renal transplant recipients: rifampicin sparing treatment protocol. Int Urol Nephrol 2002;34(4):551–553.

    Article  PubMed  CAS  Google Scholar 

  139. Park YS, et al. Clinical outcomes of tuberculosis in renal transplant recipients. Yonsei Med J 2004;45(5):865–872.

    PubMed  Google Scholar 

  140. Antony SJ, Ynares C, Dummer JS. Isoniazid hepatotoxicity in renal transplant recipients. Clin Transplant 1997;11(1):34–37.

    PubMed  CAS  Google Scholar 

  141. Manuel O, et al. Comparison of quantiferon-TB gold with tuberculin skin test for detecting latent tuberculosis infection prior to liver transplantation. Am J Transplant 2007;7(12):2797–2801.

    Article  PubMed  CAS  Google Scholar 

  142. Patel R, et al. Infections due to nontuberculous mycobacteria in kidney, heart, and liver transplant recipients. Clin Infect Dis 1994;19(2):263–273.

    Article  PubMed  CAS  Google Scholar 

  143. Jie T, et al. Mycobacterial infections after kidney transplant. Transplant Proc 2005;37(2):937–939.

    Article  PubMed  CAS  Google Scholar 

  144. Chow JW, Yu VL. Legionella: a major opportunistic pathogen in transplant recipients. Semin Respir Infect 1998;13(2):132–139.

    PubMed  CAS  Google Scholar 

  145. Peleg AY, et al. Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case-control study. Clin Infect Dis 2007;44(10):1307–1314.

    Article  PubMed  Google Scholar 

  146. Poonyagariyagorn HK, et al. Challenges in the diagnosis and management of Nocardia infections in lung transplant recipients. Transpl Infect Dis 2008;10(6):403–408.

    Article  PubMed  CAS  Google Scholar 

  147. Wilson JP, et al. Nocardial infections in renal transplant recipients. Medicine (Baltimore) 1989;68(1):38–57.

    CAS  Google Scholar 

  148. Perez MG, Vassilev T, Kemmerly SA. Rhodococcus equi infection in transplant recipients: a case of mistaken identity and review of the literature. Transpl Infect Dis 2002;4(1):52–56.

    Article  PubMed  CAS  Google Scholar 

  149. Lo A, et al. Rhodococcus equi pulmonary infection in a pancreas-alone transplant recipient: consequence of intense immunosuppression. Transpl Infect Dis 2002;4(1):46–51.

    Article  PubMed  CAS  Google Scholar 

  150. Munoz P, et al. Rhodococcus equi infection in transplant recipients: case report and review of the literature. Transplantation 1998;65(3):449–453.

    Article  PubMed  CAS  Google Scholar 

  151. Strategies for safe living following solid organ transplantation. Am J Transplant 2004;4(Suppl 10):156–159.

    Google Scholar 

  152. Siegel JD, et al. 2007 Guideline for isolation precautions: preventing transmission of infectious agents in health care settings. Am J Infect Control 2007;35(10 Suppl 2):S65–164.

    Article  PubMed  Google Scholar 

  153. Boyce JM, Pittet D. Guideline for hand hygiene in health-care settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Society for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Diseases Society of America. MMWR Recomm Rep 2002;51(RR-16):1–45, quiz CE1-4.

    PubMed  Google Scholar 

  154. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant 2004;4(Suppl 10):160–163.

    Google Scholar 

  155. Avery RK, Michaels M. Update on immunizations in solid organ transplant recipients: what clinicians need to know. Am J Transplant 2008;8(1):9–14.

    Article  PubMed  CAS  Google Scholar 

  156. Burroughs M, Moscona A. Immunization of pediatric solid organ transplant candidates and recipients. Clin Infect Dis 2000;30(6):857–869.

    Article  PubMed  CAS  Google Scholar 

  157. Pirofski LA, Casadevall A. Use of licensed vaccines for active immunization of the immunocompromised host. Clin Microbiol Rev 1998;11(1):1–26.

    PubMed  CAS  Google Scholar 

  158. Humar A, Morris M, Blumberg E, et al. Nucleic acid testing (NAT) of organ donors: is the “best” test the right test? A consensus conference report. Am J Transplant 2010;10:889–99.

    Google Scholar 

  159. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;49:1–45.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Infections Disease, Medicine Institute, The Cleveland Clinic, Cleveland, USA

    Robin K. Avery

Authors
  1. Robin K. Avery
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michelle Lard
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Titte R. Srinivas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robin K. Avery .

Editor information

Editors and Affiliations

  1. Glickman Urological & Kidney Institute, Children's Hospital of Cleveland Clinic, Euclid Ave. 9500, Cleveland, 44195, Ohio, USA

    T. R. Srinivas

  2. Glickman Urological & Kidney Institute, Cleveland Clinic, 9500 Euclid Avenue 9500, Cleveland, 44195, Ohio, USA

    Daniel A. Shoskes

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Avery, R.K., Lard, M., Srinivas, T.R. (2011). Infectious Complications: Prevention and Management. In: Srinivas, T., Shoskes, D. (eds) Kidney and Pancreas Transplantation. Current Clinical Urology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-642-9_18

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-642-9_18

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60761-641-2

  • Online ISBN: 978-1-60761-642-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation